Youssef Rahban1, Carlos D Davila1, Peter S Natov1, Navin K Kapur2. 1. The Cardiovascular Center, Tufts Medical Center, Boston, MA, 02111, USA. 2. The Cardiovascular Center, Tufts Medical Center, Boston, MA, 02111, USA. Nkapur@tuftsmedicalcenter.org.
Abstract
PURPOSE OF REVIEW: Ischemic heart disease is the most common cause of heart failure with systolic dysfunction. The progressive course of heart failure characterized by increasing levels of care and worsening quality of life often indicates an advanced stage. Similarly, cardiogenic shock remains a major clinical problem with prohibitively high mortality rates despite major advances in clinical care. Here, we review the current treatment options and available data for revascularization in patients with ischemic cardiomyopathy, advanced heart failure, and cardiogenic shock. We also explore the emerging role of Interventional Heart Failure specialist within the Heart Team. RECENT FINDINGS: Although guideline-directed medical therapy remains the cornerstone treatment strategy for patients with advanced heart failure, coronary revascularization is sometimes indicated. There is a relatively paucity of evidence regarding different revascularization strategies and the use of acute mechanical circulatory support in patients with advanced heart failure and in those presenting with cardiogenic shock. A deep understating of the physiologic and hemodynamic effects of different acute mechanical support platforms is of paramount importance in preparation for revascularization in these patients. The decision regarding revascularization in patients with coronary artery disease in the setting of left ventricular dysfunction remains challenging. Clinical decision-making in these cases requires interdisciplinary discussion and assessment of the potential long-term survival derived from surgical revascularization against its higher perioperative risk.
PURPOSE OF REVIEW: Ischemic heart disease is the most common cause of heart failure with systolic dysfunction. The progressive course of heart failure characterized by increasing levels of care and worsening quality of life often indicates an advanced stage. Similarly, cardiogenic shock remains a major clinical problem with prohibitively high mortality rates despite major advances in clinical care. Here, we review the current treatment options and available data for revascularization in patients with ischemic cardiomyopathy, advanced heart failure, and cardiogenic shock. We also explore the emerging role of Interventional Heart Failure specialist within the Heart Team. RECENT FINDINGS: Although guideline-directed medical therapy remains the cornerstone treatment strategy for patients with advanced heart failure, coronary revascularization is sometimes indicated. There is a relatively paucity of evidence regarding different revascularization strategies and the use of acute mechanical circulatory support in patients with advanced heart failure and in those presenting with cardiogenic shock. A deep understating of the physiologic and hemodynamic effects of different acute mechanical support platforms is of paramount importance in preparation for revascularization in these patients. The decision regarding revascularization in patients with coronary artery disease in the setting of left ventricular dysfunction remains challenging. Clinical decision-making in these cases requires interdisciplinary discussion and assessment of the potential long-term survival derived from surgical revascularization against its higher perioperative risk.
Authors: Gregg C Fonarow; J Thomas Heywood; Paul A Heidenreich; Margarita Lopatin; Clyde W Yancy Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: James K Kirklin; David C Naftel; Lynne Warner Stevenson; Robert L Kormos; Francis D Pagani; Marissa A Miller; Karen Ulisney; James B Young Journal: J Heart Lung Transplant Date: 2008-10 Impact factor: 10.247
Authors: William W O'Neill; Neal S Kleiman; Jeffrey Moses; Jose P S Henriques; Simon Dixon; Joseph Massaro; Igor Palacios; Brijeshwar Maini; Suresh Mulukutla; Vladimír Dzavík; Jeffrey Popma; Pamela S Douglas; Magnus Ohman Journal: Circulation Date: 2012-08-30 Impact factor: 29.690
Authors: Eric J Velazquez; Kerry L Lee; Marek A Deja; Anil Jain; George Sopko; Andrey Marchenko; Imtiaz S Ali; Gerald Pohost; Sinisa Gradinac; William T Abraham; Michael Yii; Dorairaj Prabhakaran; Hanna Szwed; Paolo Ferrazzi; Mark C Petrie; Christopher M O'Connor; Pradit Panchavinnin; Lilin She; Robert O Bonow; Gena Roush Rankin; Robert H Jones; Jean-Lucien Rouleau Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel Journal: N Engl J Med Date: 1999-08-26 Impact factor: 91.245
Authors: R T Tsuyuki; R S McKelvie; J M Arnold; A C Barretto; A C Carvalho; D L Isaac; A D Kitching; L S Piegas; K K Teo; S Yusuf Journal: Arch Intern Med Date: 2001-10-22
Authors: Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: Eur Heart J Date: 2004-09 Impact factor: 29.983
Authors: Marco Metra; Piotr Ponikowski; Kenneth Dickstein; John J V McMurray; Antonello Gavazzi; Claes-Hakan Bergh; Alan G Fraser; Tiny Jaarsma; Antonis Pitsis; Paul Mohacsi; Michael Böhm; Stefan Anker; Henry Dargie; Dirk Brutsaert; Michel Komajda Journal: Eur J Heart Fail Date: 2007-05-03 Impact factor: 15.534
Authors: Rajendra H Mehta; Joshua D Grab; Sean M O'Brien; Donald D Glower; Constance K Haan; James S Gammie; Eric D Peterson Journal: Circulation Date: 2008-02-04 Impact factor: 29.690